A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Prexasertib (Primary) ; Cetuximab; Cisplatin; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; LY 3023414; Pemetrexed
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 28 Mar 2018 Planned End Date changed from 27 Apr 2019 to 1 Feb 2020.
- 28 Mar 2018 Planned primary completion date changed from 27 Apr 2019 to 1 Feb 2020.
- 22 Aug 2017 Planned number of patients changed from 185 to 205.